To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ombitasvir regulatory update

AbbVie submitted an NDA to FDA for its all-oral regimen comprising ABT-450 plus the company's Norvir

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE